Down Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Down syndrome is a genetic disorder that causes lifelong mental retardation, developmental delays, and other problems. It varies in severity, so developmental problems range from moderate to serious. Children with Down syndrome have a distinct facial appearance. Though not all children with Down syndrome have the same features, some of the more common features are flattened facial features, small head, short neck, protruding tongue, upward slanting eyes unusual for the child’s ethnic group, and unusually shaped ears. Children with Down syndrome may also have poor muscle tone, broad, short hands with a single crease in the palm, relatively short fingers, and excessive flexibility.
The Down syndrome drugs in development market report provides an overview of the Down syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Down Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects.
What are the targets of the Down Syndrome pipeline drugs market?
Some of the targets of the Down Syndrome pipeline drugs market are Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A, Amyloid Beta A4 Protein, Alpha Synuclein, Microtubule Associated Protein Tau, Asparagine, Beta Secretase, Cannabinoid Receptor 1, Gamma Secretase, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA).
Down syndrome pipeline drugs market, by targets
For more target insights, download a free report sample
What are the mechanisms of action of the Down Syndrome pipeline drugs market?
Some of the mechanisms of action of the Down Syndrome pipeline drugs market are Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Inhibitor, Amyloid Beta A4 Protein Inhibitor, Alpha Synuclein Inhibitor, Microtubule Associated Protein Tau Inhibitor, Asparagine Depletor, Beta Secretase Inhibitor, Cannabinoid Receptor 1 Antagonist, Gamma Secretase Inhibitor, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABAAntagonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAntagonist.
Down Syndrome pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
What are the routes of administration in the Down syndrome pipeline drugs market?
The routes of administration in the Down syndrome pipeline drugs market are oral, intravenous, subcutaneous, and intramuscular.
Down syndrome pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
What are the molecule types in the Down syndrome pipeline drugs market?
The molecule types in the Down syndrome pipeline drugs market are small molecule, gene-modified cell therapy, monoclonal antibody, recombinant enzyme, and vaccine.
Down syndrome pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Which are the key companies in the Down syndrome pipeline drugs market?
Some of the key companies in the Down syndrome pipeline drugs market are AC Immune SA, Aelis Farma SAS, Alzheon Inc, Annovis Bio Inc, Avanti Biosciences Inc, Balance Therapeutics Inc, Eisai Co Ltd, Elixirgen Therapeutics Inc, F. Hoffmann-La Roche Ltd, Felicitex Therapeutics Inc, KinoPharma Inc, Laminar Pharmaceuticals SA, and Les Laboratoires Servier SAS.
Down Syndrome pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report scope
| Targets | Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A, Amyloid Beta A4 Protein, Alpha Synuclein, Microtubule Associated Protein Tau, Asparagine, Beta Secretase, Cannabinoid Receptor 1, Gamma Secretase, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA |
| Mechanisms of Action | Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Inhibitor, Amyloid Beta A4 Protein Inhibitor, Alpha Synuclein Inhibitor, Microtubule Associated Protein Tau Inhibitor, Asparagine Depletor, Beta Secretase Inhibitor, Cannabinoid Receptor 1 Antagonist, Gamma Secretase Inhibitor, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABAAntagonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAntagonist |
| Routes of Administration | Oral, Intravenous, Subcutaneous, and Intramuscular |
| Molecule Types | Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Recombinant Enzyme, and Vaccine |
| Key Companies | AC Immune SA, Aelis Farma SAS, Alzheon Inc, Annovis Bio Inc, Avanti Biosciences Inc, Balance Therapeutics Inc, Eisai Co Ltd, Elixirgen Therapeutics Inc, F. Hoffmann-La Roche Ltd, Felicitex Therapeutics Inc, KinoPharma Inc, Laminar Pharmaceuticals SA, and Les Laboratoires Servier SAS |
This report provides:
- A snapshot of the global therapeutic landscape of Down Syndrome (Genetic Disorders).
- Reviews of pipeline therapeutics for Down Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Key companies involved in Down Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- Evaluation of Down Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Down Syndrome (Genetic Disorders).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Down Syndrome (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Down Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Aelis Farma SAS
Alzheon Inc
Annovis Bio Inc
Avanti Biosciences Inc
Balance Therapeutics Inc
Eisai Co Ltd
Elixirgen Therapeutics Inc
F. Hoffmann-La Roche Ltd
Felicitex Therapeutics Inc
KinoPharma Inc
Laminar Pharmaceuticals SA
Les Laboratoires Servier SAS
ManRos Therapeutics
NeuroCircuit Therapeutics Inc
NeuroNascent Inc
Perha Pharmaceuticals SAS
Prothena Corp Plc
SanBio Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Down syndrome pipeline drugs market?
Some of the targets of the Down syndrome pipeline drugs market are Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A, Amyloid Beta A4 Protein, Alpha Synuclein, Microtubule Associated Protein Tau, Asparagine, Beta Secretase, Cannabinoid Receptor 1, Gamma Secretase, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA).
-
What are the mechanisms of action of the Down syndrome pipeline drugs market?
Some of the mechanisms of action of the Down syndrome pipeline drugs market are Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Inhibitor, Amyloid Beta A4 Protein Inhibitor, Alpha Synuclein Inhibitor, Microtubule Associated Protein Tau Inhibitor, Asparagine Depletor, Beta Secretase Inhibitor, Cannabinoid Receptor 1 Antagonist, Gamma Secretase Inhibitor, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABAAntagonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAntagonist.
-
What are the routes of administration in the Down syndrome pipeline drugs market?
The routes of administration in the Down syndrome pipeline drugs market are oral, intravenous, subcutaneous, and intramuscular.
-
What are the molecule types in the Down syndrome pipeline drugs market?
The molecule types in the Down syndrome pipeline drugs market are small molecule, gene-modified cell therapy, monoclonal antibody, recombinant enzyme, and vaccine.
-
Which are the key companies in the Down syndrome pipeline drugs market?
Some of the key companies in the Down syndrome pipeline drugs market are AC Immune SA, Aelis Farma SAS, Alzheon Inc, Annovis Bio Inc, Avanti Biosciences Inc, Balance Therapeutics Inc, Eisai Co Ltd, Elixirgen Therapeutics Inc, F. Hoffmann-La Roche Ltd, Felicitex Therapeutics Inc, KinoPharma Inc, Laminar Pharmaceuticals SA, and Les Laboratoires Servier SAS.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Genito Urinary System And Sex Hormones reports